You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 17, 2025

CLINICAL TRIALS PROFILE FOR SPINRAZA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Spinraza

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01494701 ↗ An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Completed Biogen Phase 1 2011-11-30 This objectives of this study are to evaluate the safety, tolerability, and pharmacokinetics of a single dose of nusinersen (ISIS 396443) administered intrathecally to participants with Spinal Muscular Atrophy (SMA).
NCT01494701 ↗ An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Completed Ionis Pharmaceuticals, Inc. Phase 1 2011-11-30 This objectives of this study are to evaluate the safety, tolerability, and pharmacokinetics of a single dose of nusinersen (ISIS 396443) administered intrathecally to participants with Spinal Muscular Atrophy (SMA).
NCT01703988 ↗ An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Completed Biogen Phase 1/Phase 2 2012-10-31 This study will test the safety, tolerability, and pharmacokinetics of escalating doses of nusinersen (ISIS 396443) administered into the spinal fluid either two or three times over the duration of the trial, in participants with spinal muscular atrophy (SMA). Four dose levels will be evaluated sequentially. Each dose level will be studied in a cohort of approximately 8 participants, where all participants will receive active drug.
NCT01703988 ↗ An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Completed Ionis Pharmaceuticals, Inc. Phase 1/Phase 2 2012-10-31 This study will test the safety, tolerability, and pharmacokinetics of escalating doses of nusinersen (ISIS 396443) administered into the spinal fluid either two or three times over the duration of the trial, in participants with spinal muscular atrophy (SMA). Four dose levels will be evaluated sequentially. Each dose level will be studied in a cohort of approximately 8 participants, where all participants will receive active drug.
NCT01839656 ↗ A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA) Completed Biogen Phase 2 2013-05-08 The primary objective is to examine the clinical efficacy of multiple doses of nusinersen (ISIS 396443) administered intrathecally to participants with Infantile-Onset Spinal Muscular Atrophy (SMA). The secondary objectives are to examine the safety and tolerability of multiple doses of nusinersen administered intrathecally to participants with infantile-onset SMA and to examine the cerebral spinal fluid (CSF) and plasma Pharmacokinetics (PK) of multiple doses of nusinersen administered intrathecally to participants with infantile-onset SMA.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Spinraza

Condition Name

Condition Name for Spinraza
Intervention Trials
Spinal Muscular Atrophy 10
Muscular Atrophy, Spinal 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Spinraza
Intervention Trials
Muscular Atrophy, Spinal 12
Muscular Atrophy 12
Atrophy 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Spinraza

Trials by Country

Trials by Country for Spinraza
Location Trials
United States 70
Canada 8
Japan 7
Australia 6
Italy 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Spinraza
Location Trials
New York 8
California 7
Utah 7
Massachusetts 7
Texas 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Spinraza

Clinical Trial Phase

Clinical Trial Phase for Spinraza
Clinical Trial Phase Trials
Phase 4 1
Phase 3 4
Phase 2 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Spinraza
Clinical Trial Phase Trials
Completed 4
Active, not recruiting 2
Terminated 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Spinraza

Sponsor Name

Sponsor Name for Spinraza
Sponsor Trials
Biogen 11
Ionis Pharmaceuticals, Inc. 8
Winthrop University Hospital 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Spinraza
Sponsor Trials
Industry 19
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Spinraza (Nusinersen): Clinical Trials, Market Analysis, and Projections

Introduction to Spinraza

Spinraza, also known as nusinersen, is a groundbreaking drug developed by Biogen for the treatment of Spinal Muscular Atrophy (SMA), a genetic disorder that affects motor nerve cells in the spinal cord, brain, and muscles. It was the first FDA-approved treatment for SMA and has significantly transformed the treatment landscape for this debilitating disease.

Clinical Trials Update

Ongoing and Completed Trials

Several clinical trials are ongoing or have recently concluded to further evaluate the efficacy, safety, and optimal dosing of Spinraza.

NURTURE Trial

The NURTURE trial, initiated in May 2015, is a phase 2, open-label study evaluating the safety and effectiveness of nusinersen in pre-symptomatic newborns with SMA. The latest results, published after five years of treatment, show dramatic improvements in the prognosis of SMA patients, with all participants alive, free from permanent ventilation, and achieving World Health Organization (WHO) motor milestones[4].

Higher Dose Study (DEVOTE)

The DEVOTE study, a phase 2/3 randomized, controlled trial, is assessing the safety, tolerability, and potential for greater efficacy of nusinersen at a higher dose (50 mg/28 mg) compared to the currently approved dose (12 mg). The study has shown positive topline results, indicating that the higher dose regimen can slow neurodegeneration faster and lead to meaningful clinical benefits in infants with symptomatic SMA[3].

Phase 4 Study with Zolgensma

A phase 4 study, set to complete in September 2024, is evaluating the benefit of Spinraza in patients who have received Zolgensma (onasemnogene abeparvovec) gene therapy but still have unmet clinical needs. This study aims to include 60 children and will provide insights into the combined efficacy of these treatments[1].

Other Ongoing Trials

Other trials, such as the one started in March 2020, are investigating the safety, tolerability, and potentially improved efficacy of nusinersen at higher doses. These studies are crucial for optimizing treatment protocols and addressing the remaining unmet needs in SMA management[1].

Market Analysis

Current Market Size and Growth Projections

The spinal muscular atrophy market has seen significant growth driven by advancements in gene therapy and the increasing availability of targeted treatments. As of 2023, the market size was valued at US$ 3.0 billion. It is projected to reach US$ 13.0 billion by 2034, exhibiting a Compound Annual Growth Rate (CAGR) of 14.28% during the period 2024-2034[2].

Dominant Players and Treatments

Spinraza, along with other key drugs like Zolgensma and Evrysdi, dominates the SMA treatment market. Spinraza, being the first FDA-approved treatment for SMA, has been a cornerstone in SMA management, significantly improving motor function and survival rates across different SMA types. Evrysdi, an oral alternative, offers comparable efficacy and ease of administration, further propelling market expansion[2][5].

Gene Therapy and Disease-Modifying Drugs

Gene therapy, particularly with treatments like Zolgensma, is expected to dominate the SMA market due to its one-time curative approach and long-term benefits. Disease-modifying drugs like Spinraza and Evrysdi continue to play a crucial role in managing SMA, with ongoing research aimed at enhancing their efficacy and safety profiles[5].

Market Projections

Growth Drivers

The SMA market is driven by several key factors:

  • Advancements in Gene Therapy: The development of novel gene therapies has accelerated, driven by a deeper understanding of the genetic basis of SMA and advancements in biotechnology[2].
  • Increasing Research and Development: Ongoing clinical trials and research efforts are expanding treatment options and improving outcomes for SMA patients[5].
  • Favorable Reimbursement Policies: Supportive reimbursement policies have facilitated the widespread adoption of treatments like Spinraza and Zolgensma[2].

Segment Analysis

  • Type I SMA: This segment is expected to hold a dominant position due to the high mortality and morbidity rates associated with Type I SMA, which accounts for around 60% of total SMA cases[5].
  • Gene Therapy Segment: Gene therapy is anticipated to dominate the treatment segment due to its one-time curative approach and long-term benefits[5].

Key Takeaways

  • Clinical Trials: Ongoing trials, such as the NURTURE and DEVOTE studies, are providing valuable insights into the optimal use and efficacy of Spinraza.
  • Market Growth: The SMA market is projected to grow significantly, driven by advancements in gene therapy and disease-modifying drugs.
  • Dominant Treatments: Spinraza, Zolgensma, and Evrysdi are key players in the SMA treatment market, offering effective management options for various SMA types.
  • Future Outlook: Continued research and development are expected to enhance treatment outcomes and address unmet clinical needs in SMA management.

FAQs

What is Spinraza, and how does it work?

Spinraza (nusinersen) is a disease-modifying drug that works by increasing the production of the survival motor neuron (SMN) protein, which is deficient in SMA patients. It is administered intrathecally and has shown significant efficacy in improving motor function and survival rates.

What are the current clinical trials evaluating Spinraza?

Current trials include the NURTURE trial for pre-symptomatic newborns, the DEVOTE study evaluating a higher dose regimen, and a phase 4 study assessing the benefit of Spinraza in patients treated with Zolgensma.

How is the SMA market expected to grow in the coming years?

The SMA market is projected to reach US$ 13.0 billion by 2034, with a CAGR of 14.28% during the period 2024-2034, driven by advancements in gene therapy and disease-modifying drugs.

What are the dominant treatments in the SMA market?

Spinraza, Zolgensma, and Evrysdi are the dominant treatments, with Spinraza being the first FDA-approved treatment for SMA and Zolgensma offering a one-time gene therapy approach.

What are the key drivers of the SMA market growth?

Key drivers include advancements in gene therapy, increasing research and development activities, and favorable reimbursement policies.

How does Spinraza compare to other SMA treatments like Evrysdi?

Spinraza and Evrysdi both offer effective management options for SMA, but Evrysdi provides an oral alternative, which can be easier to administer compared to the intrathecal administration of Spinraza.

Sources

  1. SMA UK: Results and Updates for Each Nusinersen Trial.
  2. Biospace: Spinal Muscular Atrophy Market Size to Reach US$ 13.0 Billion by 2034.
  3. Biogen: Biogen Announces Positive Topline Results from Study of Higher Dose.
  4. SMA UK: 5-Year Results from the Nurture Spinraza Trial Published.
  5. Biospace: Spinal Muscular Atrophy Market to Hit US$ 4,823.9 Million by 2031.
Last updated: 2025-01-01

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.